Thromb Haemost 2007; 98(02): 296-303
DOI: 10.1160/TH07-02-0140
Theme Issue Article
Schattauer GmbH

CREB binding to the hypoxia-inducible factor-1 responsive elements in the plasminogen activator inhibitor-1 promoter mediates the glucagon effect

Elitsa Y. Dimova
1   Department Chemistry/Biochemistry, University of Kaiserslautern, Kaiserslautern, Germany
,
Malgorzata M. Jakubowska
1   Department Chemistry/Biochemistry, University of Kaiserslautern, Kaiserslautern, Germany
,
Thomas Kietzmann
1   Department Chemistry/Biochemistry, University of Kaiserslautern, Kaiserslautern, Germany
› Author Affiliations
Financial support: This study was supported by the grants from Fonds der Chemischen Industrie and Deutsche Krebshilfe 106929.
Further Information

Publication History

Received 23 February 2007

Accepted after revision 21 April 2007

Publication Date:
28 November 2017 (online)

Summary

Plasminogen activator inhibitor-1 (PAI-1) controls the regulation of the fibrinolytic system in blood by inhibiting both urokinase-type and tissue-type plasminogen activators. Enhanced levels of PAI-1 are related to pathological conditions associated with hypoxia or hyperinsulinemia. In this study, we investigated the regulation of PAI-1 expression by glucagon and the cAMP/ PKA/CREB signalling pathway in the liver. Stimulation of the cAMP/PKA/CREB signalling cascade by starvation in vivo or glucagon in vitro induced PAI-1 gene expression in liver. Furthermore, this response was associated with enhanced phosphorylation of CREB. By using EMSAs we found that three promoter elements, the HRE2, E-box 4 and E-box 5, were able to bind CREB but only the HRE2 and E5 appeared to be functionally active. Reporter gene assays confirmed that cAMP induced PAI-1 gene transcription via the same element in both human and rat promoters. Interestingly, although the HRE2 was involved, the glucagon/cAMP pathway had no influence on hypoxia-inducible factor-1 (HIF-1) mRNA and protein levels. Thus, CREB binding to the HIF-1 responsive elements in PAI-1 promoter mediates the glucagon effect in the liver.

 
  • References

  • 1 Mars WM, Zarnegar R, Michalopoulos GK. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol 1993; 143: 949-958.
  • 2 Erickson LA, Schleef RR, Ny T. et al. The fibrinolytic system of thevascular wall. Clin Haematol 1985; 14: 513-530.
  • 3 Reilly CF, McFall RC. Platelet-derived growth factor and transforming growth factor-beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem 1991; 266: 9419-9427.
  • 4 Busso N, Nicodeme E, Chesne C. et al. Urokinase and type I plasminogen activator inhibitor production by normal human hepatocytes: modulation by inflammatory agents. Hepatology 1994; 20: 186-190.
  • 5 Mimuro J, Loskutoff DJ.. Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin. J Biol Chem 1989; 264: 936-939.
  • 6 Dellas C, Loskutoff DJ.. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93: 631-640.
  • 7 Fink T, Kazlauskas A, Poellinger L. et al. Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1. Blood 2002; 99: 2077-2083.
  • 8 Kietzmann T, Roth U, Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via ahypoxia response element binding the hypoxia inducible factor-1 in rat hepatocytes. Blood 1999; 94: 4177-4185.
  • 9 Dimova EY, Moller U, Herzig S. et al. Transcriptional regulation of plasminogen activator inhibitor-1 expression by insulin-like growth factor-1 via MAP kinases and hypoxia-inducible factor-1 in HepG2 cells. Thromb Haemost 2005; 93: 1176-1184.
  • 10 Juhan VI, Roul C, Alessi MC. et al. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin. Thromb Haemost 1989; 61: 370-373.
  • 11 Schneider DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 1993; 42: 1-7.
  • 12 Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002; 283: F209-F220.
  • 13 Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
  • 14 Jelinek LJ, Lok S, Rosenberg GB. et al. Expression cloning and signaling properties of the rat glucagon receptor. Science 1993; 259: 1614-1616.
  • 15 Mayo KE, Miller LJ, Bataille D. et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 2003; 55: 167-194.
  • 16 Lee CQ, Yun YD, Hoeffler JP. et al. Cyclic-AMP-responsive transcriptional activation of CREB-327 involves interdependent phosphorylated subdomains. EMBO J 1990; 9: 4455-4465.
  • 17 Gonzalez GA, Montminy MR. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 1989; 59: 675-680.
  • 18 Montminy M, Koo SH, Zhang X. The CREB family: key regulators of hepatic metabolism. Ann Endocrinol (Paris) 2004; 65: 73-75.
  • 19 Immenschuh S, Hinke V, Ohlmann A. et al. Transcriptional activation of the haem oxygenase-1 gene by cGMP via a cAMP response element/activator protein-1 element in primary cultures of rat hepatocytes. Biochem J 1998; 334: 141-146.
  • 20 Kietzmann T, Roth U, Freimann S. et al. Arterial oxygen partial pressures reduce the insulin-dependent induction of the perivenously located glucokinase in rat hepatocyte cultures: mimicry of arterial oxygen pressures by H2O2. Biochem J 1997; 321: 17-20.
  • 21 Kietzmann T, Samoylenko A, Roth U. et al. Hypoxia-inducible factor-1 and hypoxia response elements mediate the mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes. Blood 2003; 101: 907-914.
  • 22 Dimova EY, Kietzmann T. MAPK pathway and HIF-1 are involved in the induction of the human PAI-1 gene expression by insulin in the human hepatoma cell line HepG2. Ann NY Acad Sci 2006; 1090: 355-367.
  • 23 Heaton JH, Nebes VL, O’Dell LG. et al. Glucocorticoid and cyclic nucleotide regulation of plasminogen activator and plasminogen activator-inhibitor gene expression in primary cultures of rat hepatocytes. Mol Endocrinol 1989; 3: 185-192.
  • 24 Uno S, Nakamura M, Ohomagari Y. et al. Regulation of tissue-type plasminogen activator (tPA) and type-1 plasminogen activator inhibitor (PAI-1) gene expression in rat hepatocytes in primary culture. J Biochem Tokyo 1998; 123: 806-812.
  • 25 Heaton JH, Gelehrter TD. Cyclic nucleotide regulation of plasminogen activator and plasminogen activator-inhibitor messenger RNAs in rat hepatoma cells. Mol Endocrinol 1990; 4: 171-178.
  • 26 Heaton JH, Tillmann BM, Leff NS. et al. Cyclic nucleotide regulation of type-1 plasminogen activator-in hibitor mRNA stability in rat hepatoma cells. Identification of cis-acting sequences. J Biol Chem 1998; 273: 14261-14268.
  • 27 Tillmann-Bogush M, Heaton JH, Gelehrter TD. Cyclic nucleotide regulation of PAI-1 mRNA stability. Identification of cytosolic proteins that interact with an a-rich sequence. J Biol Chem 1999; 274: 1172-1179.
  • 28 Heaton JH, Dlakic WM, Dlakic M. et al. Identification and cDNA cloning of a novel RNA-binding protein that interacts with the cyclic nucleotide-responsive sequence in the type-1 plasminogen activator inhibitor mRNA. J Biol Chem 2001; 276: 3341-3347.
  • 29 Johnson MR, Bruzdzinski CJ, Winograd SS. et al. Regulatory sequences and protein-binding sites involved in the expression of the rat plasminogen activator inhibitor-1 gene. J Biol Chem 1992; 267: 12202-12210.
  • 30 Bruzdzinski CJ, Johnson MR, Goble CA. et al. Mechanism of glucocorticoid induction of the rat plasminogen activator inhibitor-1 gene in HTC rat hepatoma cells: identification of cis-acting regulatory elements. Mol Endocrinol 1993; 7: 1169-1177.
  • 31 Dimova EY, Kietzmann T. Cell type-dependent regulation of the hypoxia-responsive plasminogen acti-vator inhibitor-1 gene by upstream stimulatory factor-2. J Biol Chem 2006; 281: 2999-3005.
  • 32 Riccio A, Pedone PV, Lund LR. et al. Transforming growth factor beta 1-responsive element: closely associated binding sites for USF and CCAAT-binding transcription factor-nuclear factor I in the type 1 plasminogen activator inhibitor gene. Mol Cell Biol 1992; 12: 1846-1855.
  • 33 Hua X, Liu X, Ansari DO. et al. Synergistic cooperation of TFE3 and smad proteins in TGF-beta-induced transcription of the plasminogen activator inhibitor-1 gene. Genes Dev 1998; 12: 3084-3095.
  • 34 Dennler S, Itoh S, Vivien D. et al. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998; 17: 3091-3100.
  • 35 Allen RR, Qi L, Higgins PJ. Upstream stimulatory factor regulates E box-dependent PAI-1 transcription in human epidermal keratinocytes. J Cell Physiol 2005; 203: 156-165.
  • 36 Kvietikova I, Wenger RH, Marti HH. et al. The transcription factors ATF-1 and CREB-1 bind constitutively to the hypoxia-inducible factor-1 (HIF-1) DNA recognition site. Nucleic Acids Res 1995; 23: 4542-4550.
  • 37 Kvietikova I, Wenger RH, Marti HH. et al. The hypoxia-inducible factor-1 DNA recognition site is cAMP-responsive. Kidney Int 1997; 51: 564-566.
  • 38 Beitner-Johnson D, Millhorn DE. Hypoxia induces phosphorylation of the cyclic AMP response element-binding protein by anovel signaling mechanism. J Biol Chem 1998; 273: 19834-19839.
  • 39 Zelzer E, Levy Y, Kahana C. et al. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBOJ 1998; 17: 5085-5094.
  • 40 Forsythe JA, Jiang BH, Iyer NV. et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-4613.
  • 41 Amano H, Ando K, Minamida S. et al. Adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in vivo. Jpn J Pharmacol 2001; 87: 181-188.
  • 42 Claffey KP, Wilkison WO, Spiegelman BM. Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. J Biol Chem 1992; 267: 16317-16322.
  • 43 Thoresen GH, Sand TE, Refsnes M. et al. Dual effects of glucagon and cyclic AMP on DNA synthesis in cultured rat hepatocytes: stimulatory regulation in early G1 and inhibition shortly before the S phase entry. J Cell Physiol 1990; 144: 523-530.
  • 44 Diehl AM, Yang SQ, Wolfgang D. et al. Differential expression of guanine nucleotide-binding proteins enhances cAMP synthesis in regenerating rat liver. J Clin Invest 1992; 89: 1706-1712.
  • 45 Uno S, Nakamura M, Seki T. et al. Induction of tissue-type plasminogen activator (tPA) and type-1 plasminogen activator inhibitor (PAI-1) as early growth responsesin rat hepatocytes in primary culture. Biochem Biophys Res Commun 1997; 239: 123-128.
  • 46 Yee JA, Yan L, Dominguez JC. et al. Plasminogen-dependent activation of latent transforming growth factor beta (TGF beta) by growing cultures of osteoblastlike cells. J Cell Physiol 1993; 157: 528-534.
  • 47 Grant MB, Ellis EA, Caballero S. et al. Plasminogen activator inhibitor-1 overexpression in nonproliferative diabetic retinopathy. Exp Eye Res 1996; 63: 233-244.